Active Ingredient History

NOW
  • Now
Methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by Hoffmann-La Roche under the brand name Mircera. Mircera is a long-acting erythropoietin receptor activator (CERA) indicated for the treatment of patients with anaemia associated with chronic kidney disease. It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA). Mircera is supplied as a solution in pre-filled syringes for intravenous or subcutaneous administration. Mircera was approved for use in Europe in July 2007 by the European Commission, in September 2007 by the Swissmedic, and in November 2007 by the U.S. Food and Drug Administration for use in the United States.   Wikipedia

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$115.9306 - $1044.5539
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cera | cera (erythropoietin receptor activator) | continuous erythropoietin receptor activator | epo beta | epoetin beta | epoetin-beta | epoetin beta pegol | epoetin beta rdna | epoietin beta | methoxy polyethylene glycol epoetin beta | methoxy polyethylene glycol-epoetin beta | methoxy polyethylene glycol-epoetin-beta | mircera | pegylated epoetin beta | pegzerepoetin alfa | ro0503821

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue